会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Systems and methods for identifying miRNA targets and for altering miRNA and target expression
    • 用于鉴定miRNA靶标和改变miRNA和靶标表达的系统和方法
    • US20060185027A1
    • 2006-08-17
    • US11317660
    • 2005-12-23
    • David BartelBenjamin LewisMatthew Jones-RhoadesChristopher Burge
    • David BartelBenjamin LewisMatthew Jones-RhoadesChristopher Burge
    • A01K67/027A61K48/00G06F19/00C12N5/08C07H21/02
    • C12N15/111C12N2310/14C12N2320/11
    • The present invention generally relates to microRNAs such as vertebrate microRNA (miRNA), for example, mammalian miRNA. Various aspects of the invention are directed to the detection, production, or expression of miRNA. In one aspect, the invention provides systems and methods for identifying targets of miRNA sequences. For instance, in one embodiment, gene sequences comprising UTRs are compared with miRNA sequences to determine the degree of interaction, for example, by determining a free energy measurement between the miRNA sequence and the UTR, and/or by determining complementarity between at least a portion of the miRNA sequence and the UTR. In another aspect, the invention is directed to the regulation of gene expression using miRNA. For example, gene expression within a cell may be altered by exposing the cell to an oligonucleotide comprising a sequence that is substantially antisense to at least a portion of an miRNA region of the gene, for example, antisense to a 6-mer or 7-mer portion of the miRNA. In still another aspect, the invention is directed to the treatment of cancer. For instance, in one set of embodiments, an isolated oligonucleotide comprising a sequence that is substantially antisense to an miRNA, or a portion of an miRNA, is administered to a subject having or being at risk of cancer. Yet other aspects of the invention are directed to compositions or kits including oligonucleotides comprising a sequence that is substantially antisense to an miRNA (or a portion of an miRNA), methods of promoting any of the above aspects, or the like.
    • 本发明通常涉及微小RNA,例如脊椎动物微小RNA(miRNA),例如哺乳动物miRNA。 本发明的各个方面涉及miRNA的检测,产生或表达。 一方面,本发明提供用于鉴定miRNA序列靶标的系统和方法。 例如,在一个实施方案中,将包含UTR的基因序列与miRNA序列进行比较以确定相互作用程度,例如通过确定miRNA序列和UTR之间的自由能测量,和/或通过确定至少一个 部分miRNA序列和UTR。 另一方面,本发明涉及使用miRNA调节基因表达。 例如,可以通过将细胞暴露于寡核苷酸来改变细胞内的基因表达,所述寡核苷酸包含基本上与基因的miRNA区的至少一部分反义的序列,例如与6-聚体或7- miRNA的部分。 另一方面,本发明涉及癌症的治疗。 例如,在一组实施方案中,将包含基本上与miRNA或一部分miRNA基本反义的序列的分离的寡核苷酸施用于具有或具有癌症风险的受试者。 本发明的其它方面涉及包括寡核苷酸的组合物或试剂盒,其包含基本上与miRNA(或miRNA的一部分)反义的序列,促进任何上述方面的方法等。
    • 4. 发明申请
    • RNA sequence-specific mediators of RNA interference
    • RNA干扰的RNA序列特异性介质
    • US20070003963A1
    • 2007-01-04
    • US11474932
    • 2006-06-26
    • Thomas TuschlPhillip ZamorePhillip SharpDavid Bartel
    • Thomas TuschlPhillip ZamorePhillip SharpDavid Bartel
    • C12Q1/68C12N15/86
    • C12N15/113A01K67/0336A01K2207/05A01K2217/075A01K2227/703A01K2267/03A61K38/00C07H21/02C12N15/1079C12N15/111C12N2310/14C12N2310/321C12N2310/53C12N2330/30C12Q1/66C12N2310/3521
    • The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene finction. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
    • 本发明涉及果蝇体外系统,其用于证明dsRNA被加工成长度为21-23个核苷酸(nt)的RNA片段。 此外,当这些21-23个片段被纯化并加回到果蝇提取物时,它们在不存在长dsRNA的情况下介导RNA干扰。 因此,这些21-23个片段是RNA降解的序列特异性介质。 必须在这21-23个片段中存在可能是其特异性长度的分子信号,以招募涉及RNAi的细胞因子。 本发明包括这些21-23个片段及其用于特异性失活基因功能的用途。 使用这些片段(或具有相同或相似性质的化学合成的寡核苷酸)使得能够靶向用于哺乳动物细胞降解的特异性mRNA,其中使用长dsRNA引发RNAi通常是不实际的,可能是因为有害影响 干扰素反应。 特定基因功能的特异性靶向在功能基因组和治疗应用中是有用的。
    • 8. 发明申请
    • System and methods for identifying miRNA targets and for altering miRNA and target expression
    • 用于鉴定miRNA靶标和改变miRNA和靶标表达的系统和方法
    • US20100029003A1
    • 2010-02-04
    • US12321489
    • 2009-01-21
    • David BartelBenjamin P. LewisMatthew W. Jones-RhoadesChristopher B. Burge
    • David BartelBenjamin P. LewisMatthew W. Jones-RhoadesChristopher B. Burge
    • C12N15/85
    • C12N15/111C12N2310/14C12N2320/11
    • The present invention generally relates to microRNAs such as vertebrate microRNA (miRNA), for example, mammalian miRNA. Various aspects of the invention are directed to the detection, production, or expression of miRNA. In one aspect, the invention provides systems and methods for identifying targets of miRNA sequences. For instance, in one embodiment, gene sequences comprising UTRs are compared with miRNA sequences to determine the degree of interaction, for example, by determining a free energy measurement between the miRNA sequence and the UTR, and/or by determining complementarity between at least a portion of the miRNA sequence and the UTR. In another aspect, the invention is directed to the regulation of gene expression using miRNA. For example, gene expression within a cell may be altered by exposing the cell to an oligonucleotide comprising a sequence that is substantially antisense to at least a portion of an miRNA region of the gene, for example, antisense to a 6-mer or 7-mer portion of the miRNA. In still another aspect, the invention is directed to the treatment of cancer. For instance, in one set of embodiments, an isolated oligonucleotide comprising a sequence that is substantially antisense to an miRNA, or a portion of an miRNA, is administered to a subject having or being at risk of cancer. Yet other aspects of the invention are directed to compositions or kits including oligonucleotides comprising a sequence that is substantially antisense to an miRNA (or a portion of an miRNA), methods of promoting any of the above aspects, or the like.
    • 本发明通常涉及微小RNA,例如脊椎动物微小RNA(miRNA),例如哺乳动物miRNA。 本发明的各个方面涉及miRNA的检测,产生或表达。 一方面,本发明提供用于鉴定miRNA序列靶标的系统和方法。 例如,在一个实施方案中,将包含UTR的基因序列与miRNA序列进行比较以确定相互作用程度,例如通过确定miRNA序列和UTR之间的自由能测量,和/或通过确定至少一个 部分miRNA序列和UTR。 另一方面,本发明涉及使用miRNA调节基因表达。 例如,可以通过将细胞暴露于寡核苷酸来改变细胞内的基因表达,所述寡核苷酸包含基本上与基因的miRNA区的至少一部分反义的序列,例如与6-聚体或7- miRNA的部分。 另一方面,本发明涉及癌症的治疗。 例如,在一组实施方案中,将包含基本上与miRNA或一部分miRNA基本反义的序列的分离的寡核苷酸施用于具有或具有癌症风险的受试者。 本发明的其它方面涉及包括寡核苷酸的组合物或试剂盒,其包含基本上与miRNA(或miRNA的一部分)反义的序列,促进任何上述方面的方法等。
    • 9. 发明申请
    • RNA sequence-specific mediators of RNA interference
    • RNA干扰的RNA序列特异性介质
    • US20070003960A1
    • 2007-01-04
    • US11474738
    • 2006-06-26
    • Thomas TuschlPhillip ZamorePhillip SharpDavid Bartel
    • Thomas TuschlPhillip ZamorePhillip SharpDavid Bartel
    • C12Q1/68A01K67/033C12N1/21C12N5/06
    • C12N15/113A01K67/0336A01K2207/05A01K2217/075A01K2227/703A01K2267/03A61K38/00C07H21/02C12N15/1079C12N15/111C12N2310/14C12N2310/321C12N2310/53C12N2330/30C12Q1/66C12N2310/3521
    • The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
    • 本发明涉及果蝇体外系统,其用于证明dsRNA被加工成长度为21-23个核苷酸(nt)的RNA片段。 此外,当这些21-23个片段被纯化并加回到果蝇提取物时,它们在不存在长dsRNA的情况下介导RNA干扰。 因此,这些21-23个片段是RNA降解的序列特异性介质。 必须在这21-23个片段中存在可能是其特异性长度的分子信号,以招募涉及RNAi的细胞因子。 本发明包括这些21-23个片段及其用于特异性失活基因功能的用途。 使用这些片段(或具有相同或相似性质的化学合成的寡核苷酸)使得能够靶向用于哺乳动物细胞降解的特异性mRNA,其中使用长dsRNA引发RNAi通常是不实际的,可能是因为有害影响 干扰素反应。 特定基因功能的特异性靶向在功能基因组和治疗应用中是有用的。